ariation in the contents and discrepancies between the label and actual contents have been documented for several dietary supplement products. In 2000, Gurley et al. 1 reported a high variation in the ephedra alkaloid content of ephedracontaining dietary supplements. Other reports dating back as far as 1978 have pointed to considerable variation in products containing dehydroepiandrosterone, kava, and ginseng. 2 These variations present a threat to the public health and call into question the classification of potentially harmful substances as dietary supplements and the relatively lax regulation of these substances under the Dietary Supplement Health and Education Act (DSHEA) of 1994. 3 The DSHEA does not, for example, require consistency in the content of active components and in the recommended daily doses among different brands of a dietary supplement.
For centuries, feverfew (Tanacetum parthenium) has been used for its purported ability to decrease fever and treat headaches. 4, 5 Recent clinical data suggest that feverfew may have a moderate effect on decreasing the frequency and severity of migraine headaches when used prophylactically, but it does not appear effective for Abstract: Variations in the parthenolide content of feverfew products available to consumers were studied.
Feverfew products were analyzed for the content of parthenolide, the purported active component. The actual weight of feverfew was determined only in those products containing dried feverfew leaf. The total daily doses of feverfew leaf and parthenolide were calculated by using the instructions on each product label. Parthenolide content was determined by high-performance liquid chromatography.
The quantity of feverfew leaf in each capsule was similar to that stated on the label and ranged from 25 to 500 mg. Parthenolide content per dosage form varied 150-fold (from 0.02 to 3.0 mg), while percent parthenolide varied 5.3-fold (from 0.14% to 0.74%). If a person consumed the daily dose recommended on the label, intake of dried feverfew leaf would range from 225 to 2246 mg/day, a 10-fold variation, while intake of parthenolide would range from 0.06 to 9.7 mg/day, a 160-fold variation.
Large variations were observed in the parthenolide contents and daily intake as recommended by the labeling in commercial feverfew products. the treatment of acute migraines or for decreasing their duration. 5, 6 The beneficial effects of feverfew are believed to be mostly due to parthenolide, a sesquiterpine lactone. 4, 5 Several in vitro studies have attempted to elucidate parthenolide's mechanism of action. Capasso 7 demonstrated that aqueous extracts of feverfew containing parthenolide 50-200 µg/ mL inhibited the metabolism of arachidonic acid. The antisecretory properties of feverfew and parthenolide have been well documented in vitro. Groenewegen and colleagues 8 identified parthenolide and several other sesquiterpine lactones as compounds extracted from feverfew that inhibit the release of serotonin from platelets. They also found that parthenolide and feverfew extract prevented platelet aggregation induced by several chemicals in vitro. 9 Hayes and Foreman 10 reported that feverfew extract is a novel type of mastcell inhibitor, as shown by its antihistaminic properties in vitro. Barsby et al. 11 demonstrated the potentially toxic effect of irreversible inhibition of vasculature response in rabbit aor-Am J Health-Syst Pharm-Vol 59 Aug 15, 2002 liquid chromatographic (HPLC) assay. 15 Six single-dose samples from each product were analyzed. Samples were prepared by extraction in 100 mL of an acetonitrile b :water (9:1) mixture. Most of the feverfew products were formulated as capsules containing pure dried feverfew leaf or dried feverfew leaf and excipients. Other formulations included tablets, gelatin capsules, a glycerin extract, and an alcohol extract ( Table 1) . Capsules containing dried feverfew leaf were opened and the content removed and weighed before extraction. Gelatin capsules containing feverfew extract were assayed by opening the capsule, removing as much extract as possible, and adding both the gelatin capsule and the extract to the extraction solvent; however, we did not attempt to measure the feverfew mass, if any, in the gelatin capsules. The tablets were ground with a mortar and pestle and added to the extraction solvent; liquid formulations were added directly to the solvent. All samples were stirred for 30 minutes at room temperature and then vacuum filtered through a 0.45-µm filter. To account for solvent evaporation during ta by feverfew extract and parthenolide 50-200 µg/mL. Weber and colleagues 12 observed that parthenolide is a selective weak inhibitor of serotonin type 2A receptors but concluded that the mechanism of action of parthenolide cannot be entirely explained by this phenomenon. These findings are in contrast to the pharmacologic activity of several prescription antimigraine medications (e.g., sumatriptan) that are agonists at serotonin type 1 receptors.
There have been several reports of feverfew activity and parthenolide variation in feverfew products. Groenewegen and Heptinstall 13 reported that extracts of several commercial feverfew products inhibited serotonin release from platelets, but the activity was less than that claimed on the labels. Heptinstall et al.
14 tested the parthenolide content and antisecretory properties of multiple feverfew products available in Great Britain. Parthenolide content varied widely among the products; some contained no parthenolide at all. Parthenolide content was found to be correlated with the degree of secretory inhibition in platelets, lending weight to the belief that parthenolide is the feverfew component that contributes most to its effects.
We measured the amount of parthenolide in 21 feverfew products and compared the findings with the amounts claimed on the products' labels. In addition, we used the actual parthenolide content and the dosage recommendations on the labels to calculate the quantity of parthenolide one would consume daily if following those recommendations.
Methods
Commercially available parthenolide (99.5% purity) a was used as the reference standard. Feverfew products were purchased at retail stores in Oklahoma or via pharmacy and herbal Web sites (Table 1) . To minimize analytical interference by coeluting compounds, products containing only feverfew (i.e., singleingredient products) were analyzed. All products were stored at room temperature (25 °C) and analyzed before their expiration dates.
The parthenolide content of each feverfew product was determined by using a modified high-performance vacuum filtration, the volume of the filtered extract was measured and used in the calculation of parthenolide concentration. The residue left from initial feverfew extraction was stirred a second time in 100 mL of extraction solvent and analyzed for parthenolide content to check for incomplete extraction (five products were analyzed in this manner).
The feverfew extracts were analyzed for parthenolide concentration by using an HPLC system c calibrated with an 8-point parthenolide concentration curve prepared on the basis of synthetic parthenolide (0.2-100 µg/mL) (recalibrated each day of analysis). Before injection, a 2-mL volume of each extract was purified for HPLC analysis by passage through a 0.2-µm syringe filter.
d The autoinjector was programmed to deliver 20 µL of each purified 2-mL portion onto a C 8 column e equilibrated at 30 °C. The mobile phase consisted of water:acetonitrile (35:65) and had a flow rate of 0.5 mL/min. Under these conditions, parthenolide eluted at 5.5 minutes. With the synthetic standard, the optimal ultraviolet light (UV) absorption of parthenolide was determined by diode-array scanning (190-800 nm) to be 200 nm with a bandwidth of 10 nm (UV reference wavelength, 360 nm with a 10-nm bandwidth). Data collection and analysis were performed with ChemStation software.
f To increase the analytical accuracy for extracts with low concentrations of parthenolide, weighted linear regression analysis (1/x 2 ) of the calibration curve was used.
The parthenolide concentration of each extract was multiplied by its volume to determine the quantity of parthenolide in each extract. Six samples from each product were analyzed. The percent content of parthenolide was calculated by dividing the actual quantity of parthenolide in one dosage unit by the weight of actual dried feverfew leaf. The daily doses of feverfew and parthenolide that would be consumed if one were to follow the labeling were also calculated.
Results
The modified HPLC assay was a rapid and accurate method for analyzing parthenolide concentration in the feverfew products. 15 Complete parthenolide extraction was verified by reextraction of the extract residue left from the initial extraction of five products. No residual parthenolide was detected in the second extractions (data not shown). Therefore, it was assumed that essentially all parthenolide was extracted from each product by this method. We assayed four products at 1, 24, and 48 hours after performing extractions to ensure the extraction did not cause substantial degradation of parthenolide. None of the samples varied in parthenolide concentration by more than 5%.
All feverfew products were stored in a dry location at room temperature and analyzed before their expiration date. It was possible to directly measure the weight of dried feverfew leaf only in capsules containing pure dried feverfew leaf. The quantity of feverfew leaf in each capsule was similar to that stated on the label and ranged from 25 to 500 mg (Table 2) .
Parthenolide content was calculated in terms of milligrams per dosage unit and converted to the percentage of the weight of the feverfew content (Table 3) . (For products other than capsules of dried leaf, this calculation could not be performed because the feverfew content could not be directly measured.) The parthenolide content per dosage unit ranged from 0.02 to 3.0 mg, a 150-fold variation. The percentage of the weight of the feverfew content represented by parthenolide ranged from 0.14% to 0.74%, a 5.3-fold variation. Table 2 shows the amount of feverfew leaf a person would ingest each day if he or she was to consume the daily dose recommended on the label (if the label recommended a dosage range, the average amount was used to calculate this dose). Intake of dried feverfew leaf capsules would range from 225 mg/day (product 7) to 2246 mg/day (product 6), a 10-fold variation. Table 3 shows the variation in daily parthenolide intake that would occur if each product was taken according to the label instructions. Again, if the label recommended a dosage range, the average of that range was used. (In the case of product 21, this was difficult to determine, because the instructions recommended "one or more capsules per day.") Excluding product 13, for which we could not detect parthenolide, the daily intake of parthenolide ranged from of parthenolide (about 160-fold). This variation represents an industrywide inconsistency in the content and preparation of feverfew and in the daily dose recommended by manufacturers. While questions exist as to whether parthenolide is the sole contributor to feverfew's purported efficacy, 16 the inconsistencies in parthenolide content in the products analyzed in this study are unacceptable. Although not studied here, it would be reasonable to suspect that other potentially active components of feverfew are also inconsistently represented in these products.
Several possibilities may explain the variation in parthenolide content. Parthenolide breaks down over time. 14, 17 In addition, the source of the feverfew may have an impact. For example, feverfew grown in Germany has a higher parthenolide content than feverfew grown in Mexico or Yugoslavia.
14 Even though all the products in this study were pur-0.06 mg/day (product 9) to 9.7 mg/ day (product 3), a 162-fold variation.
Discussion
In the United States, herbal preparations are legally considered dietary supplements but are perceived and used by most patients as medications. This use may occur to augment or even replace prescription drug therapy. Because of the overwhelming popularity of dietary supplements, many product brands exists for any one supplement. In this study, we analyzed 21 feverfew products for feverfew leaf and parthenolide contents and calculated the daily intake of these two components on the basis of the label recommendations. The relatively high variation in daily parthenolide and feverfew leaf intake that we identified adds to the growing body of literature demonstrating a lack of pharmaceutical consistency among dietary supplement products. Especially important is the high variation in the daily dose chased in the United States and analyzed before their expiration date (except those products whose labeling did not state an expiration date), the plant sources of the products studied may have caused the variations in parthenolide content observed.
Feverfew may be moderately effective in preventing migraine headaches, and patients will continue to use this herb. Feverfew may have a role in migraine prevention, but more rigorous scientific evidence of its efficacy and safety is needed. The findings of this study suggest that it would be appropriate to advise patients who choose to use feverfew to use one brand exclusively.
The high variation in the daily doses of parthenolide that consumers receive from feverfew products is not acceptable. Standardized preparations of feverfew should be established so that patients can be sure that they are getting the same amount of active compound each time they use a feverfew product.
Conclusion
Large variations were observed in the contents of dried feverfew leaf and parthenolide, a major active ingredient, in commercial feverfew products.
a Sigma-Aldrich Co., St. Louis, MO 63178, lot 119H3853.
b Fisher Scientific International, Inc., Fair Lawn, NJ 0 7413, lot 962372.
c Agilent 1100 Series system with the following components: a vacuum degasser (G1312A), a quaternary pump (G1311A), an autoinjector (G1313A), a diode-array detector (G1315B), and a thermostatted column compartment (G1316A) (Agilent Technologies, Palo Alto, CA 94303).
d Fisher Scientific International. 
